5.30
2.51%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Learn to Evaluate (GLUE) using the Charts - Stock Traders Daily
Potential Price Increase for Monte Rosa Therapeutics Inc (GLUE) After Recent Insider Activity - Knox Daily
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com South Africa
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com Australia
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com India
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com
Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - US Post News
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth - Simply Wall St
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 9.7% in August - Defense World
Meeder Asset Management Inc. Purchases Shares of 10,050 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Versant Venture Capital Vi, L. Sells 541,897 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock - Defense World
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com Australia
Wedbush Reiterates Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Versant Venture Capital Vi, L. Sells 9,269 Shares - MarketBeat
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com India
Monte Rosa Therapeutics' (GLUE) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 3.3% - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 3.3% - Defense World
Monte Rosa Therapeutics Inc’s Banking’s 100-Day Moving Average at 4.77: Will the Stock Break Through? - The InvestChronicle
Market Insights: Monte Rosa Therapeutics Inc (GLUE)’s Notable Drop of -3.44, Closing at 6.17 - The Dwinnex
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth - Yahoo Finance
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com India
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com Australia
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com UK
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - GlobeNewswire
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - StockTitan
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 - Defense World
Vanguard Group Inc. Grows Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 at Wells Fargo & Company - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Monte Rosa Therapeutics: Q2 Earnings Snapshot - New Haven Register
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Thehour.com
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
Price T Rowe Associates Inc. MD Has $35.93 Million Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
Price T Rowe Associates Inc. MD Buys 155,880 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Acadian Asset Management LLC Raises Stock Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) & Finch Therapeutics Group (NASDAQ:FNCH) - Defense World
Head to Head Comparison: TScan Therapeutics (NASDAQ:TCRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 29.3% in June - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - American Banking and Market News
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Bakersfield.com
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - GlobeNewswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Yahoo Finance
Recent uptick might appease Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) institutional owners after losing 39% over the past year - Simply Wall St
These 2 ‘Strong Buy’ Penny Stocks Could Jump at Least 300%, Says Piper Sandler - Markets Insider
Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Monte Rosa Therapeutics' (GLUE) Overweight Rating Reaffirmed at Piper Sandler - Defense World
Piper Sandler maintains overweight rating on Monte Rosa shares By Investing.com - Investing.com Australia
Monte Rosa Therapeutics maintains Buy rating on MRT-2359 trial By Investing.com - Investing.com Canada
Gitlab director Karen Blasing sells shares worth $157,500 By Investing.com - Investing.com
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Piper Sandler maintains overweight rating on Monte Rosa shares By Investing.com - Investing.com UK
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):